Uncategorized
Xeris Pharma: A Rising Star in the Pharmaceutical Landscape (XERS)
In a recent enlightening interview at the H. C. Wainwright’s 25th Annual Global Investment Conference, Xeris Pharma’s promising trajectory was laid bare for all to see. With CEO Paul Edick and CFO Steve Pieper at the helm, the company’s future has never looked brighter. Here’s why every investor should be bullish about Xeris Pharma. 1….
J.P. Morgan Healthcare Conference 2023 Transcript
Transcription may have some errors – apologize in advance Paul Edick – I would remind everyone to pay attention to our forward looking statements. Investing is always a risk. We’ll start out with an overview of the company. Xeris has a very diversified revenue base. We have three marketed assets, all growing record level. I’ll…
Q1 2022 Earning Call Audio & Transcription
Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Updated with Seeking Alpha transcript: Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30…
Q4 2021 Earning Call Audio & Transcription
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey – SVP, IR and Corporate Communications Paul Edick – Chairman and CEO Steve Pieper – CFO Conference Call Participants Roanna Ruiz – SVB Leerink Vamil Divan – Mizuho Securities David Amsellem – Piper Sandler Operator Hello everyone….
2021 Q3 Earnings Call Recording
Transcription is computer automated and may not be 100% accurate, but until Seeking Alpha provides their transcript, this is better than nothing. Once Seeking Alpha provides the call transcript, this automated transcription will be removed. Edit: Transcription has been updated using Seeking Alpha | Source Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10,…
XERS – Bull Case Shows 217% Upside while Bear Case Shows 42% Upside
The tl;dr is that a bull case evaluation for XERS shows an upside of 217% with PT $14.21 and a bear case evaluation shows an upside of 42% with PT $6.38. Note that this does not factor in the possibility of a short squeeze which could increase the price past its fundamental value. Given the…
An Undeserved Valuation: Xeris Pharmaceuticals
Source: Fortune Team | Jan 23 | Updated: Jan 24 | Blatantly undervalued and under-followed, Xeris has the potential to shine significantly in 2021, ascending as a true Fortune Alert( alerted initially in $2s). Take a look at our thoughts in a nutshell: Overview Xeris is a specialty pharmaceutical company that offers bold, innovative formulation technologies:…
- 1
- 2